This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Neuronetics Presents NeuroStar TMS...
Tech medical research

Neuronetics Presents NeuroStar TMS Data at CTMSS

Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentation of new real-world data by Neuronetics on its NeuroStar Advanced Therapy at a prominent medical conference could positively impact investor confidence in Neuronetics, potentially leading to an increase in its stock price. This event reinforces the scientific leadership of Neuronetics in the medical technology sector, particularly in neurohealth disorders.

Medical Technology Healthcare
Event Summary

Neuronetics, a medical technology company, announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting. The company will present new real-world data from its TrakStar database, highlighting the effectiveness of NeuroStar Advanced Therapy for major depressive disorder and in adolescents. These presentations aim to advance the understanding of transcranial magnetic stimulation (TMS) for mental health conditions. Cory Anderson, Chief Technology Officer at Neuronetics, emphasized the importance of this expanded real-world evidence. Neuronetics will also demonstrate NeuroStar's navigation capabilities, enabled by its partnership with ANT Neuro, at the PULSES Course during the meeting. This participation underscores Neuronetics' commitment to innovation and evidence-based treatment options for patients with depression and other mental health disorders. Neuronetics also operates Greenbrook TMS treatment centers, which offer NeuroStar Advanced Therapy and Esketamine.

Entities Involved
stock
Neuronetics
Neuronetics is the primary company involved, presenting new real-world data on its NeuroStar Advanced Therapy at the CTMSS Annual Meeting, reinforcing its leadership in TMS research and potentially boosting its market position.
Importance 100.0 Sentiment 45.0
oth
NeuroStar Advanced Therapy
NeuroStar Advanced Therapy is the product of Neuronetics, and the new data presented at CTMSS reinforces its effectiveness and leadership in transcranial magnetic stimulation for mental health conditions.
Importance 90.0 Sentiment 40.0
ngo
Clinical TMS Society
The Clinical TMS Society is hosting the annual meeting where Neuronetics is presenting its research, serving as a key platform for disseminating advancements in TMS.
Importance 70.0 Sentiment 20.0
per
Cory Anderson
Cory Anderson, Chief Technology Officer at Neuronetics, emphasized the importance of expanding real-world evidence for TMS, highlighting Neuronetics' commitment to scientific analysis.
Importance 30.0 Sentiment 20.0
priv
ANT Neuro
ANT Neuro is a partner of Neuronetics, enabling NeuroStar's navigation capabilities demonstrated at the CTMSS PULSES Course.
Importance 15.0 Sentiment 10.0
stock
Greenbrook TMS
Greenbrook TMS operates treatment centers offering NeuroStar Advanced Therapy and Esketamine, expanding the reach of these treatments.
Importance 10.0 Sentiment 15.0
oth
Esketamine
Esketamine is a prescription medicine offered at Greenbrook TMS centers for treatment-resistant depression, mentioned as an additional treatment option.
Importance 5.0 Sentiment 10.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration has cleared the NeuroStar Advanced Therapy System for various conditions, providing regulatory validation for the treatment.
Importance 5.0 Sentiment 0.0
cnt
United States
Greenbrook TMS operates treatment centers across the United States, indicating the geographical scope of Neuronetics' operations.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.